FOREWORD

After years of neglect, tuberculosis (TB) is now acknowledged as a major global health problem. The world's growing number of refugees and displaced persons are at risk of both TB, and of inadequate TB treatment. In order to provide guidance to organizations (both government and non-government) on the implementation of effective TB control programmes in refugee situations, the World Health Organization (WHO) and the Office of the High Commissioner for Refugees (UNHCR) have collaborated to produce this Manual.

Effective TB control programmes:

- cure TB patients
- reduce the transmission of TB; and
- prevent the development of drug resistant TB organisms

The principles of TB control presented in this document are simple. A TB control programme should be integrated into the primary health care services, and be consistent with the overall goals of relief activities, namely to:

- reduce the suffering of the affected community; and
- facilitate the resumption of normal and productive lives

All aspects of a relief programme should adhere to the following criteria:

- foster ownership, participation, and capacities of the affected population
- contain the displacement of a population where possible
- avoid potentially harmful relief measures, such as large and unsanitary camps, inappropriate medical supplies, and culturally insensitive practices
- minimize dependency on external resources
- ensure consistent and transparent communication between relief providers and communities; and
- ensure that the needs of local communities in proximity to refugee and displaced persons camps have access to assistance programmes, when indicated

Overcrowding in camps is undesirable and is often associated with inadequate access to water and sanitation, lack of land for farming, loss of community initiative and over-dependency, disruption to normal social patterns, and considerable psychological problems. Each one of these issues will affect a TB control programme.

In conflict settings, or famine situations communities should be held together and relief assistance should be provided directly to the village or town, whenever feasible. This may make the provision of public health services (including TB diagnosis and treatment) logistically more difficult; however, the overall benefit to the community is considerable.

When camps are unavoidable, dependency should be minimized by including refugees and displaced persons in the planning of health programmes and ensuring that community health workers play an active role in implementing the programme. Programmes for refugees and displaced persons should be designed with their eventual repatriation or resettlement in mind. Plans for eventual repatriation should be developed from the outset.

TB control should not be used as a pretext for discouraging repatriation or any other durable solution to the plight of refugees and displaced communities. Suggestions for dealing with patients undergoing TB treatment in the event of a repatriation are presented.
The meeting recognized the humanitarian and epidemiological catastrophe facing the world unless effective TB control programmes are implemented in refugee situations. Uncoordinated TB control activities will lead to the development of drug resistance. TB could then become untreatable in remote areas of the world and the risk of untreatable TB will progress beyond isolated communities.

The meeting called on non-government organizations and private healthcare workers to stop distributing anti-TB drugs outside integrated TB control programmes.

The meeting called for full participation of other international organizations such as the International Organization on Migration and the International Federation of Red Cross and Red Crescent Societies, and non-government organizations to assist in the full implementation of TB control programmes in refugee situations consistent with the WHO TB control strategy.

This Manual requires field testing in a number of different situations.

Comments on the document are welcome and should be sent to:

Global Tuberculosis Programme  
World Health Organization  
CH-1211  
Geneva 27  
Switzerland  
Fax: +41 22 791 4199
EXECUTIVE SUMMARY

This Manual is intended to inform operational agencies, donor agencies and field managers of the issues related to TB control in refugee situations. The Manual will serve as a tool in the implementation, monitoring and evaluation of TB control programmes in refugee situations.

TB control is not a priority in the immediate emergency phase when mortality and malnutrition rates are high due to measles, diarrhoeal disease, meningitis, and malaria. The priorities during this phase are the provision of adequate food, water, shelter, sanitation, basic drugs and the control of common acute communicable diseases.

A TB control programme should not commence until death rates have been reduced to less than 1 per 10,000 population per day, basic needs are provided, and essential clinical services and supplies are available.

A TB control programme should be implemented only if the security situation is stable and the camp population are expected to remain for at least 6 months. Funding should be available for at least 12 months, along with sufficient medical supplies and trained staff.

Since TB is more common, both in countries of origin and in host countries, the involvement of the national TB programme (NTP) of the host country in the implementation of the TB programme is essential.

The priority of a TB control programme is to identify and treat infectious patients, and ensure that they become non-infectious as soon as possible. Successful cure of infectious patients will reduce transmission and prevent new patients from occurring. Patients become non-infectious within two weeks of commencing the treatment if drugs are taken regularly.

In addition to smear-positive pulmonary TB patients, severely ill patients with non-pulmonary TB are to be treated in the TB programme. Other non-infectious TB patients should not be included the TB programme until it has demonstrated that cure rates are satisfactory.

The recommended strategy for curing infectious TB patients is the WHO TB control strategy (DOTS), which is implemented by providing the correct combination of TB drugs for 6 or 8 months, and observing patients swallowing their medicines. This is especially important during the first two months of treatment.

TB patients co-infected with HIV respond well to standard TB treatment. Since TB is more common in HIV infected individuals, and because many refugees and displaced persons may come from, or seek refuge in, countries with a high prevalence of HIV infection, TB control and HIV programmes should be carefully coordinated.

TB is an energy wasting disease. Many refugees may also be suffering from malnutrition which is exacerbated by TB. TB treatment will normally lead to an increased need for calories, therefore nutritional rehabilitation may be an important component of a TB control programme in refugee situations.

TB control programmes should be integrated into the primary health care services for the refugee population; however, a TB Coordinator should be appointed for approximately every 50,000 refugees.
GLOSSARY

ACID-FAST BACILLI (AFB)
Bacteria which do not lose their stain when exposed to acid during the staining process e.g. Mycobacterium tuberculosis (the TB organism).

ACTIVE CASE FINDING
Suspects are vigorously looked for within the community.

ANNUAL RISK OF TB INFECTION
The chance of an uninfected person becoming infected with the TB organism in a one year period.

BACILLE CALMETTE-GUERIN (BCG)
A live vaccine against TB derived from an attenuated strain of Mycobacterium bovis.

BACTERICIDAL
A drug which kills bacteria.

BACTERIOSTATIC
A drug which stops bacteria from growing

CHRONIC PATIENTS
Patients who have completed a retreatment course of anti-TB medication but have failed to become cured. They are infectious to others and they may excrete drug resistant organisms.

COHORT ANALYSIS
An assessment of the treatment outcomes of a group of patients who were diagnosed, registered and planned to have the same treatment, within a defined period (usually 3 months, one year prior to analysis).

CONTINUATION PHASE OF TREATMENT
The second period of treatment, after the initial phase, when treatment is maintained with a reduced number of drugs.

DIRECTLY OBSERVED THERAPY
Each dose of medication administered to the patient is observed by the health staff to ensure it is taken and swallowed.

EXTRA-PULMONARY TB
TB of organs other than the lungs. This includes TB of the pleura, lymph nodes, abdomen, genito-urinary tract, skin, joints and bones, and meningitis.

HAEMOPTYSIS
Sputum containing blood.

INCIDENCE
The number of new patients of a disease in a defined population during a specified period of time.

INITIAL PHASE OF TREATMENT
The first period of treatment when a combination of drugs are given to kill as many of the TB organism as possible, as quickly as possible, for a period of 2-3 months.

MANTOUX TEST
A skin test to assess previous BCG vaccination, or infection with the TB organism.
MULTIPLE DRUG RESISTANT (MDR) TB
Strains of TB organism which are resistant to, at least, both isoniazid and rifampicin.

MYCOBACTERIUM TUBERCULOSIS
The bacteria (organism) which causes TB.

PASSIVE CASE FINDING
Screening by sputum microscopy of persons presenting themselves at a health facility with respiratory symptoms (e.g. cough > 3 weeks).

PULMONARY TB
Tuberculosis affecting the lungs.

SHORT COURSE CHEMOTHERAPY (SCC)
Treatment with TB drugs for 6 or 8 months duration based on the combination of at least 3 major TB drugs: isoniazid, rifampicin and pyrazinamide.

SMEAR CONVERSION RATES
The rate at which a group of patients changes from sputum smear positive to smear negative.

SMEAR-NEGATIVE PULMONARY TB

* either: a patient who fulfils all the following criteria:
  - two sets (taken at least 2 weeks apart) of at least two sputum specimens negative for acid-fast bacilli on microscopy
  - radiographic abnormalities consistent with pulmonary TB and a lack of clinical response despite one week of a broad-spectrum antibiotic, and
  - a decision by a physician to treat with a full curative course of anti-TB chemotherapy.

* or: a patient who fulfils all the following criteria:
  - severely ill
  - at least two sputum specimens negative for acid-fast bacilli by microscopy
  - radiographic abnormalities consistent with extensive pulmonary TB (interstitial or miliary), and
  - a decision by a physician to treat with a full curative course of anti-TB chemotherapy.

* or: a patient whose initial sputum smears were negative, who had sputum sent for culture initially, and whose subsequent sputum culture result is positive.

SMEAR-POSITIVE PULMONARY TB:

* either: a patient with at least two sputum specimens positive for acid-fast bacilli by microscopy;

* or: a patient with at least one sputum specimen positive for acid-fast bacilli by microscopy and radiographic abnormalities consistent with pulmonary TB;

* or: a patient with at least one sputum specimen positive for acid-fast bacilli by microscopy, which is culture positive for M. Tuberculosis.

SPUTUM SMEAR EXAMINATION
A laboratory technique where acid-fast bacilli (AFB) are stained with the Ziehl-Neelsen method, then identified by microscope.
ABBREVIATIONS

CHW
Community Health Worker

DOTS
Directly-observed therapy, short-course

GTB
Global Tuberculosis Programme

HIV
Human immunodeficiency virus

IUATLD
International Union Against Tuberculosis and Lung Disease

NGO
Non-governmental organization

NTP
National Tuberculosis Programme

TB
Tuberculosis

UNICEF
United Nations Children's Fund

UNHCR
Office of the United Nations High Commissioner for Refugees

WHO
World Health Organization
1. TUBERCULOSIS (TB)

1.1 GLOBAL BURDEN OF TB

In 1996 there were about 9 million new cases of TB with 3 million deaths, worldwide. These deaths comprise 25% of all avoidable adult deaths in developing countries. 95% of patients, and 98% of deaths, from TB occur in developing countries. 75% of TB patients in developing countries are in the economically productive age group (15-50 years).

The increase the global burden of TB is due to a combination of:

- population growth
- rapid urbanization
- increasing poverty
- spread of HIV (in some regions of the world); and
- ineffective TB control programmes leading to the development of multiple drug resistant organisms

1.2 NATURAL HISTORY OF TB

It is estimated that up to one-third of the world's population is infected with the TB organism. Once infected, a person stays infected for many years, probably for life. The vast majority (90%) of people who are infected with the TB organism do not develop active TB disease. In these healthy, asymptomatic, but infected individuals, the only evidence of infection may be a positive tuberculin skin test.

Transmission occurs by airborne spread of infectious droplets. The source of infection is a person with TB of the lung who is coughing.

Infected persons can develop active TB disease at any time. The chance of developing TB disease is greatest shortly after infection and then steadily lessens as time goes by. Various physical or emotional stresses may trigger the progression of infection to disease. The most important trigger is weakening of immune resistance, especially by HIV infection. TB can affect most tissues and organs, but most commonly the lungs.

Without treatment, after 5 years, 50% of active pulmonary TB patients will be dead, 25% will be healthy (self-cured by a strong immune defence), and 25% will remain ill with chronic, infectious TB.

1.3 TB IN REFUGEE SITUATIONS

The number of refugees, displaced persons and other persons of concern to UNHCR was estimated to be more than 26 million in 1996. Over 85% of refugees originate from, and remain within, countries with high burdens of TB.

Refugees are at particularly high risk of developing TB. Coexistent illness and the poor nutritional status of many refugees weaken their immune system and make them more vulnerable to developing TB. The crowded living conditions of most refugee camps facilitate the transmission of TB from infectious patients.

The HIV epidemic affects many countries with large refugee populations, particularly in sub-Saharan Africa. TB notifications have trebled in parts of Africa over the past decade, much of this increase being attributed to the HIV epidemic. Refugee camps in high HIV prevalence countries could be experiencing an even more dramatic rise in TB burden.
KENYA
The incidence of new infectious TB patients in camps was 4 times the rate in the local population.

TB is also a major cause of death in refugee situations.

SOMALIA
In a refugee camp in 1989, one quarter of all adult deaths were due to TB. In two camps in eastern Sudan in 1990, 38% and 50% of all adult deaths were due to TB.

1.4 HIV/TB

In some countries (particularly sub-Saharan Africa), 30-70% of TB patients are infected with HIV. Compared with a non-HIV infected person, an HIV infected person is 25 times more likely to progress from infection to active disease. As well as being at greater risk of developing severe disease, HIV infected people are also at greater risk of developing serious side-effects from TB drugs.

TB is the leading cause of death amongst people infected with HIV. When a HIV /AIDS prevention programme is established in a camp or emergency setting, education on HIV prevention should be provided to TB patients through the TB clinics. TB clinics are also suitable places for the distribution of condoms.

TB patients with concurrent HIV infection respond well to TB treatment but may have more side effects from TB drugs. If a TB patient is infected with HIV, monitor for opportunistic infections, and refer to a doctor for assessment.

TB patients should not be routinely tested for HIV.

The symptoms and signs of TB in patients who are infected with HIV are the same as in non-infected individuals. Spread from the lungs to other parts of the body is common and may result in the severer forms of TB (e.g. meningitis). This is particularly so in children.

Thioacetazone should be avoided because severe, even life-threatening, reactions occur more frequently in HIV co-infected individuals. It is not recommended for use in refugee situations.
2. IMPLEMENTATION OF TB CONTROL PROGRAMMES IN REFUGEE SITUATIONS

The aim of TB control in refugee situations is to reduce the morbidity, mortality and transmission of TB.

The objectives for TB control should be to cure at least 85% of detected infectious patients and to detect at least 70% of existing cases.

2.1 INITIATION

When the basic health services are able to meet the daily needs and care of all acute respiratory infections and acute respiratory symptoms (e.g. pneumonia), for both adults and children, TB services should be developed.

The following criteria are essential before a decision to implement a TB control programme is made:

- data indicate that TB is an important health problem
- the emergency phase is over (death rates < 1 per 10,000 population per day)
- basic needs of water, adequate food, shelter and sanitation are available
- essential clinical services and basic drugs are available
- security in, and stability of, the camp envisaged for at least 6 months
- sufficient funding for at least 12 months; and
- laboratory services for sputum smear microscopy will be available

TB can be effectively treated using the WHO TB control strategy (DOTS). The essential component of the strategy is to provide TB drugs for 6 or 8 months under direct observation of healthcare workers.

The WHO TB control strategy involves:

- a commitment to TB control by authorities (at many levels)
- passive case-finding
- diagnosis by smear microscopy
- treatment by directly observed therapy, using short-course chemotherapy; and
- monitoring TB patients by a standardized recording and reporting system

Therefore a TB control programme needs to ensure the:

- availability of adequate funds
- establishment of a system of regular drug supply
- establishment and maintenance of a sputum microscopy service
- application of the WHO recommended recording and reporting systems; and
- training health care workers in the management and application of TB control

2.2 SITUATION ANALYSIS

Once the decision to implement a TB control programme is made, an assessment of the situation should be carried out. Information which should be collected includes:

- funding available to implement a TB control programme
Drug procurement, establishment of a laboratory and training, may take over 3 months to complete. The decision to commence a TB programme should therefore be taken as early as possible. Funding must be assured for at least 12 months of programme activity, preferably longer. There should be agreement between all partners (NTP, NGOs) on the TB control policies to be implemented.

The key steps involved in setting up a TB control programme are as follows:

- lead agency identified i.e. NGO, NTP
- budget prepared
- TB Coordinator (possibly 1 per 50,000 population) with a contract for at least 12 months appointed
- agreement with representatives of NTP of host country on:
  - integration of refugee TB control programme with NTP
  - drug regimens to be used
  - coverage of the local population in the TB control programme
  - referral of seriously-ill patients to local hospitals
  - laboratories suitable for quality control of smear examination
  - procurement of drug stocks and reagents
  - procedures for follow up of cases in repatriation phase
  - programme evaluation
- staff needs assessed, job descriptions developed, and staff recruited
- staff trained - TB coordinators, nurses, community health workers, laboratory technicians
- secure storage facilities identified
- production of local TB control protocol; and
- reporting system established.

KENYA

In 1992 in the north-eastern part of Kenya, an influx of refugees from Somalia attending the local TB treatment centres led to the near collapse of these services. As a result, the National Leprosy and TB Programme developed guidelines for the diagnosis and treatment of refugees with TB inside the camps based on its existing practices. Voluntary workers from the refugee community supported by staff from the Ministry of Health and Médecins sans Frontières supervised patients taking their drugs daily during the 7 months of treatment. UNHCR ensured that funds and drugs were continuously available.
Laboratory
The correct diagnosis and classification of TB cases depends on a reliable microscopy laboratory that can perform sputum examinations.\(^1\)

### 2.3 TRAINING

Training is a key element in a successful TB control programme. All involved in the programme require basic knowledge of TB, its diagnosis and appropriate treatment. Training must be conducted by people who are themselves well trained in TB control. The NTP, WHO and NGOs who specialize in TB control may be sources of such trainers.

Often health workers who have worked in TB control in their home country may be found amongst the refugees or displaced people. These persons may be able to provide useful background information on community knowledge, cultural beliefs, regimens, and practices used previously. They could also be employed as supervisors of treatment.

Staff training should occur locally where possible, using existing materials adapted to the local setting. The topics covered should include the following:

- transmission of TB
- clinical signs and symptoms of TB
- diagnosis of TB, including the role of the laboratory
- treatment of TB, including dosages and side-effects of drugs
- patient education and follow-up
- management of a TB clinic
- record keeping and medical supplies management
- community education; and
- monitoring and evaluation.

### 2.4 LOCAL TB PROTOCOL

A simple protocol for implementation of the TB programme at the local level should be developed through consultation with all agencies involved in TB care. It should be adapted for the local situation. Copies should be distributed to all treatment facilities.

In selecting the drug regimen, a WHO recommended short-course chemotherapeutic regimen should be used. Consideration should be given to the protocol of the host NTP, and of the country of origin of refugees.

### 2.5 SUPPLY OF DRUGS AND EQUIPMENT

Required Steps:

- identify the responsible officer for procurement of drugs and materials
- identify potential suppliers and their costs
- estimate supply needs, cost of freight, insurance, customs duties / taxes
- estimate time from placing the order to arrival of drugs at central store
- prepare a budget for the cost of drugs, laboratory supplies and other requirements

---

obtain a firm commitment for funding
find suitable storage facilities
purchase the drugs and supplies; and
monitor usage and inspect stores and recording periodically.

2.6 **FINANCIAL MANAGEMENT**

The following items must be included in the budget estimates:

- health staff salaries
- drugs and other medical supplies
- laboratory equipment and reagents
- stationary and other clinic needs; and
- transport.
3. MANAGEMENT OF TB IN REFUGEE SITUATIONS - ADULTS

3.1 DIAGNOSIS OF TB IN ADULTS

The most important symptoms in the selection of TB suspects in adults (over 15 years of age) are the following:

- productive cough > 3 weeks, or
- haemoptysis; and
- significant weight loss.

Patients with TB may also have other symptoms (which are more common, but less suggestive) such as:

- chest pain
- breathlessness
- fever / night sweats
- tiredness; and
- loss of appetite.

In refugee situations, it is unusual to have ready access to x-ray facilities. It is the priority of the health services to detect the sources of infection by sputum-microscopy, and cure them.

Each TB suspect should have 3 sputum samples examined by light microscopy. The chances of finding TB organisms are greater with 3 sputum samples than with one or two samples. Secretions build up in the airways overnight, therefore an early morning sputum sample is more likely to contain the TB organism than a sample later in the day.

In practice a suspect provides sputum samples in the following manner:

- Day 1
  Sample 1 - Suspect provides an "on the spot" sample under supervision on presentation to the health facility. Then the suspect is given a sputum container to take home for an early morning sample the following morning.

- Day 2
  Sample 2 - Suspect brings an early morning sputum sample.
  Sample 3 - Suspect provides another "on the spot" sample.

Smears should be stained using the Ziehl-Neelsen method. Any TB suspect with two positive smears is a TB patient, who must then be registered and commenced on anti-TB treatment.

If the initial 3 smears are negative, but pulmonary TB is still suspected because of persistent symptoms, the suspect should be given broad-spectrum antibiotics (e.g. amoxicillin or co-trimoxazole, but not rifampicin), treated for acute respiratory infection for at least one week, and re-examined two weeks after the first sputum examination by sputum smear microscopy. Specific anti-TB medication should not be commenced unless the presence of AFB is confirmed.

80% of all pulmonary TB cases are expected to be sputum smear positive: 60-65% are identified at the first examination, the remainder on subsequent examination. If at the second examination all specimens are negative, it is unlikely that the suspect has TB. Nevertheless, if it is possible to access x-ray facilities and / or refer to a hospital, an x-ray compatible with TB should encourage further sputum examination. In the absence of a compatible x-ray the suspect is not a TB patient.
In exceptional circumstances, a compatible x-ray read by an experienced physician in the presence of symptoms consistent with TB will lead to the diagnosis of pulmonary TB in smear negative cases. These patients are not a priority for treatment, as they are not contagious at the time.

Additional cases of TB may be found among close contacts of known smear-positive cases, either family members or persons sleeping in the same shelter. Symptomatic contacts should be screened, using the procedures described above.

### CRITERIA OF DIAGNOSIS OF PULMONARY TB IN ADULTS

**Smear-positive pulmonary TB:**

- **either:** a patient with at least two sputum specimens positive for acid-fast bacilli by microscopy;
- **or:** a patient with at least one sputum specimen positive for acid-fast bacilli by microscopy and radiographic abnormalities consistent with pulmonary TB;
- **or:** a patient with at least one sputum specimen positive for acid-fast bacilli by microscopy, which is culture positive for M. Tuberculosis.

**Smear-negative pulmonary TB:**

- **either:** a patient who fulfils all the following criteria:
  - two sets (taken at least 2 weeks apart) of at least two sputum specimens negative for acid-fast bacilli on microscopy
  - radiographic abnormalities consistent with pulmonary TB and a lack of clinical response despite one week of a broad-spectrum antibiotic, and
  - a decision by a physician to treat with a full curative course of anti-TB chemotherapy.

- **or:** a patient who fulfils all the following criteria:
  - severely ill
  - at least two sputum specimens negative for acid-fast bacilli by microscopy
  - radiographic abnormalities consistent with extensive pulmonary TB (interstitial or miliary), and
  - a decision by a physician to treat with a full curative course of anti-TB chemotherapy.

- **or:** a patient whose initial sputum smears were negative, who had sputum sent for culture initially, and whose subsequent sputum culture result is positive.

### ZAIRE - GOMA

In 1994, 750,000 Rwandan refugees arrived in Goma, distributed in 4 camps in the Kivu region. With the close co-ordination of the Zairean NTP, 538 TB cases were detected (1995). 430 pulmonary TB cases (390 sputum smear positive, and 40 sputum smear negative) and 108 extra-pulmonary TB cases were registered. Smear positive cases represented 91% of pulmonary TB cases, and 72% of all TB cases. These results illustrate that high quality diagnosis, high quality laboratory services, and prioritization of the programme are achievable under difficult circumstances even in a population where estimated HIV prevalence was 60%.
Extrapulmonary TB should not be neglected in the refugee situation, especially in young adults and children.

Some cases will be easy to diagnose:

- peripheral lymphadenitis, with swelling of cervical or axillary lymph nodes, chronic evolution with sinus and production of caseous discharge; and
- ascites due to TB peritonitis, without liver disease, or other symptoms of cirrhosis, with lymphocytes and protein in the fluid extracted by puncture.

Other cases will be suspected, but should be referred to a hospital:

- for assessment and definitive diagnosis (severe, life-threatening forms, with dyspnoea, coma or other neurological symptoms (miliary TB, TB meningitis)); or
- for x-ray, in case of suspected TB pericarditis, TB arthritis, osteomyelitis (including Pott's disease (vertebral TB)).

### 3.2 TREATMENT

Once diagnosis is made, and before beginning treatment, every patient must be questioned carefully as to whether or not they have ever taken anti-TB drugs before.

The patient should be classified according to the following criteria:

- site of disease (pulmonary or extra-pulmonary)
- severity of disease
- bacteriological status (assessed by sputum microscopy); and
- history of anti-TB treatment (new or previously treated).

New case - a patient who has never had treatment for TB or who has taken anti-TB drugs for less than four weeks:

- sputum smear positive pulmonary TB
- sputum smear negative pulmonary TB; and
- extra-pulmonary TB.

Previously treated case - a patient who has ever received anti-TB treatment for more than one month.

This group of patients comprises:

- return after interruption (common among recent refugees)
- failure - a patient who while on treatment remained, or became again, smear-positive five months, or later after commencing treatment. It is also a patient who was initially smear-negative before starting treatment and became smear-positive after the second month of treatment
- relapse - a patient who has been declared cured of TB in the past by a physician, after one full course of chemotherapy, and has become sputum smear-positive; and
- chronic - a very small number of previously treated cases are (a patient who remained or became again smear-positive after completing a fully supervised, standardized retreatment regimen)
3.3 TREATMENT REGIMENS AND TREATMENT CATEGORIES

The chemotherapeutic regimes are based on standardized combinations of 5 essential anti-TB drugs:

- rifampicin (R)
- isoniazid (H)
- pyrazinamide (P)
- ethambutol (E); and
- streptomycin (S).

Each of the standardized chemotherapeutic regimens consists of 2 phases:

- initial (intensive) - 2-3 months, with 3-5 drugs given daily under direct observation, to maximally reduce the number of TB organism. The number of drugs used relates to the risk of failure of treatment due to bacterial resistance; and
- continuation - 4-6 months, with 2-3 drugs given 3 times a week under direct observation, or in some cases (e.g. during repatriation of refugees) 2 drugs for 6 months given daily unsupervised, but in fixed-dose combination form.

All doses of rifampicin containing regimens are observed by staff.

Actual swallowing of medication must be checked.

Treatment Categories

Treatment categories are essential for prioritization of TB treatment according to public health risk - Category I is the highest priority, Category III the lowest.

Category I

These patients are:

- smear-positive persons who have never previously been treated or have only received treatment for less than one month
- severely ill patients with other forms of TB (new smear-negative pulmonary TB with extensive parenchymal involvement, and new cases of severe forms of TB); and
- children with a score of 7 or more on the score chart (See TB in Children - Chapter 4).

The recommended regime is for 6 months. For the first 2 months of treatment (initial (intensive) phase), rifampicin, isoniazid, pyrazinamide and ethambutol under direct supervision are given daily, or three times a week (streptomycin can replace ethambutol). At the end of the second month, most patients will have a negative result on sputum microscopy - they can then progress to the second stage of treatment - the continuation

---

2 Regimens are written in short form with the number of months the medication is to be given in front of the letter and the doses per week written after the letter. If there is no number after the letter, a daily dosage is given. The symbol "/" separates the different phases of the therapy, e.g. 2 RHZE / 4 H3R3 means that for the first 2 months of treatment, rifampicin, isoniazid, pyrazinamide and ethambutol are given daily. This is followed by 4 months of rifampicin and isoniazid given regularly but each only given 3 times per week.

3 This category includes patients with TB meningitis, disseminated TB, pericarditis, peritonitis, bilateral or extensive pleurisy, vertebral disease with neurological complications, and intestinal and genitourinary disease.
phase. This phase lasts for 4 months, with rifampicin and isoniazid given 3 times per week, under direct supervision.\footnote{Daily self-administered ethambutol and isoniazid may be used in the continuation phase for 6 months, so this treatment regime takes a total of 8 months.}

Whatever the reason, if the sputum smear examination is positive at the end of the second month, the initial phase is prolonged for a third month. The patient then starts the continuation phase. If the sputum smears are still positive at the end of the fifth month, this patient is classified a treatment failure. The patient is re-registered, and commences a full course of the retreatment regimen as a Category II patient.

Drug dose is adjusted for weight gain at the end of the initial phase (2\textsuperscript{nd} or 3\textsuperscript{rd} month).

**Category II**

Patient who were previously treated and are now sputum-smear positive, include:

- treatment after interruption
- treatment failure; and
- relapse after treatment

These patients should receive a standardized retreatment regimen, fully supervised throughout both phases of treatment.

For the first 3 months of treatment (initial phase), rifampicin, isoniazid, pyrazinamide and ethambutol are given daily. This regimen is supplemented by streptomycin daily for the first 2 months. The continuation phase of this regimen is followed by 5 months of rifampicin, isoniazid and ethambutol given 3 times per week.

Sputum-smear examination is performed at the end of the initial phase of treatment (at the end of three months), during the continuation phase of treatment (at the end of the fifth month) and at the end of treatment (at the end of the eighth month). If the patient is sputum-smear positive at the end of the third month, the initial phase of treatment is extended for one more month. Patients who are still positive at the end of the fourth month, progress to the continuation phase, regardless.

**Category III**

These patients are:

- smear-negative pulmonary patients (with limited parenchymal involvement); and
- non-serious extra-pulmonary disease in adults and children (including symptomatic primary disease)

All Category III patients should receive two months of rifampicin, isoniazid and pyrazinamide daily, followed by four months of alternate day isoniazid and rifampicin (if it is decided that treatment is to be commenced). These patients are not high priority, and should not be treated in the initial stages of the TB programme, or if resources are scarce.
### ESSENTIAL ANTI-TB DRUGS – RECOMMENDED DOSAGE

**OPTIMAL AND RANGE**

<table>
<thead>
<tr>
<th>Drug</th>
<th>Daily Administration (mg/kg)</th>
<th>3x Per Week (mg/kg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>H</td>
<td>5 (4-6)</td>
<td>10 (8-12)</td>
</tr>
<tr>
<td>R</td>
<td>10 (8-12)</td>
<td>10 (8-12)</td>
</tr>
<tr>
<td>Z</td>
<td>25 (20-30)</td>
<td>35 (30-40)</td>
</tr>
<tr>
<td>S</td>
<td>15 (12-18)</td>
<td>Not recommended</td>
</tr>
<tr>
<td>E</td>
<td>15 (15-20)</td>
<td>30 (25-35)</td>
</tr>
</tbody>
</table>

### RECOMMENDED TREATMENT REGIMEN FOR EACH TREATMENT CATEGORY

<table>
<thead>
<tr>
<th>Treatment Category</th>
<th>Patients</th>
<th>Initial (Intensive) Phase</th>
<th>Continuation Phase</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>New smear-positive pulmonary TB; new smear-negative pulmonary TB with extensive parenchymal involvement; new cases of severe forms of extra-pulmonary TB</td>
<td>2 EHRZ (2 SHRZ) or 2 E3 H3 R3 Z3 (2 S3 H3 R3 Z3)</td>
<td>4 H3 R3 (6 HE)</td>
</tr>
<tr>
<td>II</td>
<td>Sputum smear-positive; relapse; treatment failure; treatment after interruption</td>
<td>2 SHRZE / 1 HRZE</td>
<td>5 H3 R3 E3</td>
</tr>
<tr>
<td>III</td>
<td>New smear-negative pulmonary TB (other than in Category I); new less severe forms of extra-pulmonary TB</td>
<td>2 HRZ or 2 H3 R3 Z3</td>
<td>4 H3 R3 (6 HE)</td>
</tr>
</tbody>
</table>

---

# RECOMMENDED TREATMENT REGIMENS FOR CATEGORY I PATIENTS

<table>
<thead>
<tr>
<th>Pretreatment Body Weight (kg)</th>
<th>Initial (intensive) Phase</th>
<th>Continuation Phase</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2 Months (daily)</td>
<td>4 Months (3 x per week)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Isoniazid + Rifampicin (100mg+150mg tablet, or 150mg+300mg tablet)</td>
</tr>
<tr>
<td>&lt;33</td>
<td>2 (100mg+150mg tablet)</td>
<td>2</td>
</tr>
<tr>
<td>33-50</td>
<td>3 (100mg+150mg tablet)</td>
<td>3</td>
</tr>
<tr>
<td>&lt;50</td>
<td>2 (150mg+300mg tablet)</td>
<td>4</td>
</tr>
</tbody>
</table>

*When Isoniazid and Rifampicin is given daily in the Continuation Phase, the doses given are the same as in the initial phase.*
## RECOMMENDED TREATMENT REGIMENS FOR CATEGORY II PATIENTS

<table>
<thead>
<tr>
<th>Pretreatment Body Weight (kg)</th>
<th>Initial (intensive) Phase</th>
<th>Continuation Phase</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>3 Months (daily)</td>
<td>5 Months (3 x per week)</td>
</tr>
<tr>
<td></td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td>3</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td>4</td>
<td>3</td>
</tr>
</tbody>
</table>

- **Isoniazid + Rifampicin (100mg+150mg tablet, or 150mg+300mg tablet)**
- **Pyrazinamide (400mg or 500mg tablet)**
- **Ethambutol (400mg tablet)**
- **Streptomycin (1g base powder, for injection)**
  - Isoniazid + Rifampicin (100mg+150mg tablet)
  - Isoniazid (300mg tablet)
  - Ethambutol (400mg tablet)

*Streptomycin is only given for the first 2 months of the initial (intensive) phase.*

*When Isoniazid and Rifampicin is given daily in the Continuation Phase, the doses given are the same as in the initial phase.*
## RECOMMENDED TREATMENT REGIMENS FOR CATEGORY III PATIENTS

<table>
<thead>
<tr>
<th>Pretreatment Body Weight (kg)</th>
<th>Initial (intensive) Phase</th>
<th>Continuation Phase</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2 Months (daily)</td>
<td>4 Months (3 x per week)</td>
</tr>
<tr>
<td>Isoniazid + Rifampicin (100mg+150mg tablet, or 150mg+300mg tablet)</td>
<td>Pyrazinamide (400mg or 500mg tablet)</td>
<td>Isoniazid + Rifampicin (100mg+150mg tablet)</td>
</tr>
<tr>
<td>&lt;33</td>
<td>2 (100mg+150mg tablet)</td>
<td>2</td>
</tr>
<tr>
<td>33-50</td>
<td>3 (100mg+150mg tablet)</td>
<td>3</td>
</tr>
<tr>
<td>&lt;50</td>
<td>2 (150mg+300mg tablet)</td>
<td>4</td>
</tr>
</tbody>
</table>

*When Isoniazid and Rifampicin is given daily in the Continuation Phase, the doses given are the same as in the initial phase.*
3.4 TREATMENT ADHERENCE

Ensuring patient adherence is mandatory to ensure the cure of the patient programme. Conditions for producing adherence include:

- directly observation of treatment
- home visits to trace non-compliers and patients who interrupt their treatment (defaulters)
- good relationship between staff and patient
- continuing education programme for staff, patients and families, and the community; and
- clinic setting acceptable to patients and staff.

Active follow-up of defaulters by the healthcare worker responsible for that patient must be in place. All TB patients should be followed-up, even after missing one attendance.

**ZAIRE - GOMA**

TB control programmes operating within the refugee camps in 1995, covering a population of 750,000 recruited 357 new smear positive TB patients; the cured + treatment-completed rate was 71%, 13% died, 8% defaulted and 6% transferred out. The high death rate was related to the high prevalence of HIV.

**THAI - CAMBODIAN BORDER**

A programme tailored for the Khmer refugees in the camps achieved an excellent adherence rate. After their sputum was found to be positive for the TB organism, each patient was required to attend a 4 day course for 1 hour per day. This course covered most aspects of TB, its spread and its treatment. A housemate was chosen to help take responsibility for the TB patient receiving their course of treatment. Patients were required to teach their housemate what had been taught at the course. A home visit was made by members of the TB staff, including the health worker who would follow the patients throughout their course of treatment. The visit was to evaluate household contacts for symptoms of TB and to assess how much the housemate had learnt from the patient. Multiple interviews occurred prior to acceptance into the programme. It was felt necessary that patients had a stable residence, were not looking for missing family members and thus likely to leave, and had a regular source of food (to ensure they stayed for the duration of treatment). If the staff agreed to take the patient into the programme, a contract was signed by all the parties before treatment could begin. The refugee was required to commit himself to attend the clinic regularly for the entire duration of the treatment.

Food incentives have been successfully used in some programmes but their use is controversial. Extra food may help the nutritional state of patients, and may act as a powerful incentive to attend for treatment. The use of material incentives is discouraged.
SOMALIA

A successful TB programme was established despite the security problems in the country. Here excellent adherence rates were achieved and new patients were attracted from other areas as word spread of the programme’s success. All patients received treatment in accordance with the WHO TB control strategy. In addition to the medications they were provided with 3 meals per day, lodging for themselves and their family if they were not from the local area, and education for their children. A mosque was provided in the premises for use by patients and their families. A contract was signed by the patient, their supporter and the TB staff prior to the commencement of therapy. Initially, TB was a stigmatized disease in the area and many patients avoided medical assistance for fear of being labeled. This is changing as more patients are being cured.

3.5 PATIENT MANAGEMENT

The majority of TB patients can be treated on an outpatient basis, unless they are severely ill. They do not require isolation. Outpatient treatment is given daily or three times a week by the nurse or the health worker responsible for the health facility in the camp. These services should be fully integrated into the general health services for that population.

Indications for hospitalization are:

- severe disease (e.g. meningitis requiring high quality diagnosis, nursing care and regular observation)
- serious complications of treatment (e.g. severe skin reactions, hypersensitivity, jaundice)
- other concomitant diseases with potential deleterious impact on treatment (e.g. malaria, diabetes, hepatic insufficiency, renal insufficiency); and
- logistical difficulties (e.g. providing treatment for a sick patient from a remote village who can’t walk to receive treatment)

In hospital, TB patients recently started on treatment should be separated from other patients (especially those infected with HIV) in a well ventilated area. Each patient should have a covered container for sputum and the contents must be disposed of in a safe manner. The patients and their families should receive regular education on preventive measures such as covering the mouth when coughing. Refugees may be at risk of malnutrition. Nutritional rehabilitation is important in the treatment of TB in refugee situations. TB causes severe weight loss, even in people with adequate nutritional intake. Nutritional supplements during the intensive phase should be given, if possible, and continued in the continuation phase if signs of malnutrition persist.

3.6 TB TREATMENT DURING PREGNANCY

Pregnant women are treated with the same regimens as others but streptomycin must not be given. All other drugs are safe in pregnancy and lactation. Ethambutol may be substituted for streptomycin. All women should be asked if they are pregnant before commencing treatment. They should be asked to notify the TB clinic if they become pregnant during the course of TB treatment.
4. MANAGEMENT OF TB IN REFUGEE SITUATIONS - CHILDREN

Cases of TB in children usually represent about 10% of all TB patients. The source of transmission of TB is usually an adult, often a family member with smear positive TB. TB in children is a general disease which may affect any part of the body. Children rarely have smear positive TB, so they are rarely infectious.

In refugee situations with a large number of children, extra-pulmonary forms of TB should be suspected, diagnosed and treated appropriately. Often, this requires referral to a hospital for x-ray and special examinations (e.g. lumbar puncture).

Children with headache, change of temperament, recent squint or ocular muscle paralysis or dyspnoea should be suspected of meningitis. TB is one, although rare, cause of meningitis (meningococcal meningitis is a more common cause in the refugee setting). Definitive diagnosis requires hospital referral.

Children with high fevers, dyspnoea, gastro-intestinal symptoms, confusion (i.e. those with suspicion of acute miliary tuberculosis) must also be referred to hospital for assessment and diagnosis.

Suspected bone and joint TB, or pleural effusions also requires referral.

Commoner forms of extra-pulmonary disease can be diagnosed and treated in a camp situation (e.g. cervical or auxiliary lymphadenitis, peritonitis with ascites).

The diagnosis of TB in children should be carefully considered in a child if there is:

- an illness lasting for more than 10 days
- a history of close contact with a TB patient
- a poor response to antibiotic therapy
- a poor response to one month of nutritional rehabilitation
- weight loss or abnormally slow growth
- loss of energy; or
- increasing irritability and drowsiness over 2 weeks

The drug regimens used for children are the same as for adults with the exception that streptomycin should be avoided. Drug dosages must be calculated using the child's weight. Adjustments may have to be made during the course of the treatment as the child may rapidly regain lost weight.

For infants of newly diagnosed smear-positive mothers, breast-feeding should continue. The infant should not be separated from the mother. Transmission is likely to have occurred already and the infant is at greater risk of dying from other causes if breast-feeding is stopped. If the infant is well, s/he should be given isoniazid as prophylaxis for 6 months. BCG should be given one week after ceasing the isoniazid. If the infant becomes unwell, TB should be suspected.

Score Chart[^10]

A score sheet has been developed to improve the diagnosis of childhood TB. A score of 7 is considered suggestive of TB and treatment is recommended. If the score for the child is 6 or less, a 7 day course of antibiotics should be given and repeated if there is no clinical improvement. The response is again assessed after the second week. If there has been no improvement, anti-TB treatment is recommended.

[^10]: Adapted from, Crofton J, Horne N, Miller F. Clinical Tuberculosis, MacMillan, TALC and IUATLD, 1992 (Courtesy Dr. Keith Edwards, University of Papua New Guinea).
Nutritional rehabilitation should be given to a child suspect for at least one month.

**TO BE USED AFTER 1 MONTH OF NUTRITIONAL REHABILITATION**

<table>
<thead>
<tr>
<th>FEATURE</th>
<th>0</th>
<th>1</th>
<th>3</th>
<th>SCORE</th>
</tr>
</thead>
<tbody>
<tr>
<td>LENGTH OF ILLNESS</td>
<td>LESS THAN 2 WEEKS</td>
<td>2-4 WEEKS</td>
<td>MORE THAN 4 WEEKS</td>
<td></td>
</tr>
<tr>
<td>NUTRITION (WEIGHT)</td>
<td>ABOVE 80% FOR AGE</td>
<td>BETWEEN 60% AND 80%</td>
<td>LESS THAN 60%</td>
<td></td>
</tr>
<tr>
<td>FAMILY TB PAST OR PRESENT</td>
<td>NONE</td>
<td>REPORTED BY FAMILY</td>
<td>PROVED SPUTUM POSITIVE</td>
<td></td>
</tr>
</tbody>
</table>

**SCORE FOR OTHER FEATURES IF PRESENT**

- Positive tuberculin test (3 points)
- Large painless lymph nodes, firm, soft, sinus in neck, axilla, groin (3 points)
- Unexplained fever, night sweats, no response to malaria treatment (2 points)
- Malnutrition, not improving after 4 weeks (3 points)
- Angle deformity of spine (4 points)
- Joint swelling, bone swelling or sinuses (3 points)
- Unexplained abdominal mass or ascites (3 points)
- Central nervous system signs (change in temperament, fits or coma) (3 points)

**TOTAL SCORE**

When score is 7 or more, treat for TB.
5. PREVENTION OF TB IN REFUGEE SITUATIONS

5.1 PREVENTION

The diagnosis and cure of infectious cases of TB is the most effective method of preventing the transmission of TB.

BCG has been shown to be effective in preventing severe forms of TB such as meningitis in children. As overcrowding and malnutrition are common in many refugee situations, the risk of TB transmission to children is increased. BCG is strongly recommended for all newborn children in refugee situations and any children up to the age of 5 years who have not already received it. The vaccination of newborns should be incorporated into the immunization programme for all children. Re-vaccination is not recommended.

Other methods of preventing TB transmission include ensuring good ventilation and reducing crowding in health clinics, and ensuring hospitalized patients are kept in a separate ward for the first two weeks of treatment. Particular care must be made to separate infectious TB patients from HIV positive individuals.

Isoniazid prophylaxis is not recommended in refugee situations, except for children being breast-fed by smear positive mothers. If the child is well, BCG vaccination should be postponed and isoniazid should be given to the child for 6 months. In the event of a sudden disruption to the programme, isoniazid may be stopped, and BCG should be given before the child leaves the refugee camp (preferably after a one week interval).

5.2 HEALTH EDUCATION

Key elements of community education are:

- removal of stigmatization of TB
- early (self) referral of TB suspects; and
- the importance of adherence to treatment

The most important messages to teach are:

- coughing spreads diseases including TB
- TB is curable
- good treatment is the best prevention
- anyone may contract TB
- early diagnosis and treatment stops TB spreading and cures the patient quickest
- all patients must take the full course of treatment
- TB can cause a cough lasting more than 3 weeks, chest pain, shortness of breath and fevers or sweats
- treatment makes patients non-infectious in two weeks, but cure takes 6 or 8 months.
- incomplete treatment contributes to spreading disease
- treatment must be completed even when the patient feels better
- controlling TB is a community responsibility
- covering the mouth whenever coughing or sneezing to prevent the spread of lung diseases
- all patients should be treated sympathetically and with respect
• early treatment is important for best results and to prevent spread, especially to family members
• children are especially at risk if not treated and may develop severe, even fatal disease
• treatment is necessary for at least 6 months although the patient feels better much sooner; and
• failure to complete the treatment may result in a recurrence which may be impossible to treat and spread of serious disease to others, especially children.

Diagrams should be used as much as possible - a high literacy rate should not be assumed.

Cured patients are often helpful teachers and supporters of new patients.
6. MONITORING OF TB CONTROL PROGRAMMES IN REFUGEE SITUATIONS

6.1 RECORDING AND REPORTING

Good record keeping is an essential requirement for a successful programme.

Because the treatment is long, and adherence is essential for a successful outcome (cure), the individual patient must be closely followed.

It is important to assess the overall progress and success rate of the programme. This requires detailed information about the patients' progress even if they have not yet completed the course of therapy.

Key requirements are:

- accurate record keeping
- regular reporting
- regular analysis; and
- regular feedback to all staff involved

Records which must be kept are:

- suspects register
- laboratory register
- individual patient's record; and
- central TB register

It is essential for an orderly referral process to be in place. The critical link is between the Laboratory Register and the Central TB Register. The TB co-ordinator must check that all patients with positive sputum results are entered in the Central TB Register in a timely manner. If the laboratory is situated near the clinic, this person should check the laboratory register daily. If daily review is not practical, twice weekly is suggested. The same staff member must also be responsible for contacting the relevant clinic so the patient can commence treatment promptly. Follow-up to ensure the patient has actually commenced the treatment is essential. Close supervision to ensure these crucial links are made is of vital importance.

6.2 EVALUATION OF THE PATIENT

If possible, patients should be reviewed by a doctor weekly for the first month, then every 2 weeks during the second month, and monthly for the duration of their treatment.

Essential indicators to measure individual patient progress are:

- sputum-smear result after 2 months of treatment
- if positive at 2 months, sputum microscopy to be repeated at 3 months after an additional month of intensive phase therapy
- sputum-smear result after 4 months (5 months for Category II) of therapy; and

• sputum-smear result at the completion of the 6 months (8 months for Category II) of therapy

Two smears must be negative before a patient can be declared cured. The laboratory must examine all specimens, even if the specimen, after treatment, is non-purulent.

6.3 OUTCOME DEFINITIONS

At the end of the treatment course for each patient, the TB Coordinator should record the treatment outcome as follows:

**Cure**
patient who is smear negative at (or one month prior to) the completion of treatment and on at least one previous occasion

**Treatment completed**
patient who has completed treatment but in whom smear results are not available on at least 2 occasions prior to the completion of treatment

**Treatment failure**
patient who remains or becomes again smear positive at 5 months or later, after starting treatment

**Died**
patient who dies for any reason during the course of chemotherapy

**Treatment after interruption (default)**
patient whose treatment has been interrupted for more than 2 consecutive months before the end of course of treatment, or

**Transferred out**
patient who has been transferred to another treatment centre and whose treatment results are not known.

6.4 EVALUATION OF THE LABORATORY

The following information should be routinely reported by the laboratory:

• number of sputum samples examined and percentage positive
• number of new smear-positive sputum patients diagnosed
• number of extra-pulmonary patients diagnosed
• result of quality assurance tests; and
• regular review of records

All smears must be reported as being saliva or sputum.

6.5 EVALUATION OF TB PROGRAMME PERFORMANCE

A monthly health center report should be prepared and be integrated with the health information system in the region. In the refugee situation, UNHCR or UNICEF usually has such a system in operation to monitor diseases which are known to be a problem. The TB section of this report merely includes the number of new TB patients diagnosed (smear-positive and extra-pulmonary) by age (under 5, and over 5 years) and the number of TB patients whose treatment is completed and are cured. These figures are not sufficient to evaluate a TB programme.
Evaluation of TB programme occurs in 3 stages:

- case finding
- early treatment result (smear conversion by 2-3 months)\(^{12}\); and
- cohort analysis for treatment outcome (12-15 months after registration)

**Case Finding**

The number of:

- new patients, who were sputum smear positive
- elapse patients, who were sputum smear positive; and
- other patients being treated (e.g. extra-pulmonary)

should be reported every 3 months from each diagnosis and treatment centre.

**Early Treatment Result (Smear Conversion by 2-3 Months)**

In order to anticipate the result of treatment (which would otherwise not be available for another 12-15 months) it is essential to monitor the sputum smear conversion rates achieved at the end of 2 and / or 3 months of treatment.

The expected smear conversion rate, even in refugee situations, should be higher than 80%. If a programme is achieving conversion rates of 80% or less, it should be reviewed immediately - there is either:

- misclassification of patients
- DOT is not being properly applied; or
- patient follow-up is poor

Corrective measures should be devised and applied. Evaluation of smear conversion by 2-3 months can be reported independently of the reporting forms, or assessed by the TB Coordinator during supervisory visits to the laboratory.

**Cohort Analysis**

A cohort consists of patients who were diagnosed, registered and planned to have the same treatment within a defined period (12-15 months prior to analysis). Evaluation of outcome of treatment is based on the analysis of two groups of patients:

- new sputum smear positive pulmonary cases receiving Category I regimen; and
- retreatment sputum smear positive pulmonary cases receiving Category II regimen

**Quarterly Report on New Cases and Relapses of Tuberculosis**

This report complies with the epidemiological and administrative requirements for the notification of new and relapse cases diagnosed in the previous 3 months. The report includes the total number of pulmonary smear positive cases (divided into new and relapses), pulmonary smear negative and extrapulmonary cases which were diagnosed and registered during a quarter. The failure, chronic and return after interruption cases are not included in this report; they are not notifiable cases. The new pulmonary smear positive cases are classified by age and sex; all the other types of patients are classified only by sex.

The report is prepared by the TB Coordinator based on the information entered into the Central TB Register. The report is submitted to the NTP.

\(^{12}\) The analysis of the 3 month smear conversion rate is not done until 3 months after the end of the quarter during which the cohort was registered.
## POSSIBLE CAUSES AND SOLUTIONS FOR POOR TREATMENT OUTCOMES

<table>
<thead>
<tr>
<th>If there were too many</th>
<th>And the cause was</th>
<th>Then the possible solutions are</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>DEATHS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>High prevalence of HIV</td>
<td>Multiple interventions to minimise HIV transmission</td>
</tr>
<tr>
<td></td>
<td>TB was diagnosed late</td>
<td>Make sure health workers properly assess symptoms in TB suspects and send sputum for examination. ID any impediments to access to health facilities, and correct them</td>
</tr>
<tr>
<td></td>
<td>Trading in drugs and materials</td>
<td>Investigate thoroughly and take appropriate action</td>
</tr>
<tr>
<td></td>
<td>Poor quality medications may be being used</td>
<td>Review the tendering and procurement procedures</td>
</tr>
<tr>
<td></td>
<td>A low smear conversion rate at 2 (3) months</td>
<td>Make sure that there is 100% supervision of dose administration</td>
</tr>
<tr>
<td></td>
<td>Patients do not take all the medication</td>
<td></td>
</tr>
<tr>
<td><strong>FAILURES</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Primary resistance to both Rifampicin and Isoniazid</td>
<td>Devise local protocol – initiate all previously treated patients (irrespective of duration of previous treatment) on Category II treatment</td>
</tr>
<tr>
<td></td>
<td>Inappropriate regimen for the specific situation, eg. Retreatment patients given a regimen for new patients</td>
<td>Improve supervision of the health facility</td>
</tr>
<tr>
<td></td>
<td>Prescription of an inappropriate regimen for smear-positive patients previously treated with anti-TB medications</td>
<td>Ask the clinic supervisor to make sure staff knows which regimen to prescribe to each type of patient according to the NTP. Check the regimen prescribed in the register and on the TB treatment card. Are medications being traded?</td>
</tr>
<tr>
<td></td>
<td>Patients were not given proper health education</td>
<td>Make sure that proper health education is provided to patients on a continuous basis and in a way that they can understand it</td>
</tr>
<tr>
<td></td>
<td>Patients were not given proper health education. Unfriendly behaviour of the health staff</td>
<td>Help authorities to understand the importance of the diagnosis of TB</td>
</tr>
<tr>
<td></td>
<td>Slow delivery of medications at the health unit</td>
<td>Pay attention to staff morale and enhance training</td>
</tr>
<tr>
<td></td>
<td>Non-compliers and defaulters were not followed-up</td>
<td>Make sure health workers understand the importance of tracing patients. Arrange tracing of patients who disappear especially those who are smear positive</td>
</tr>
<tr>
<td></td>
<td>Patients are released and not followed-up, or not transferred correctly</td>
<td>Increase supervision. Review arrangements between NTP and community health services</td>
</tr>
<tr>
<td><strong>DEFAULTERS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Patients who were erroneously considered “transferred out” when they had the intensive phase and the continuation phase treated indifferent districts</td>
<td>Patients should be registered in the place where they are receiving treatment. In well established programmes or area TB coordinator should trace patients who transfer/move to the region and find out their treatment outcomes</td>
</tr>
<tr>
<td><strong>TRANSFERED OUT</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
7. EVOLUTION OF TB CONTROL PROGRAMMES IN REFUGEE SITUATIONS

7.1 EXPANSION OF TB CONTROL PROGRAMMES IN REFUGEE SITUATIONS

If the TB control programme achieves conversion rates of at least 85% at 2(3) months of treatment in new smear-positive and relapse cases, in at least one clinic, this implies that the TB control policies can be implemented effectively.\textsuperscript{13} At this stage, expansion from that clinic can occur. The clinic should be designated a 'Demonstration and Training Centre'.

Expansion should be gradual. Many staff will need to be trained effectively. Higher level supervisors will need to assist as trainers, as the ongoing operations of the Demonstration and Training Centre must not be neglected.

Training should include the health staff at peripheral health facilities who have responsibilities of case-finding and treatment of TB patients. Laboratory staff must also be trained before expansion can proceed.

7.2 MAINTENANCE PHASE OF A PROGRAMME

Most patients are expected to complete their treatment at the site in which they was originally begun; however, a plan should be devised to deal with patients who transfer into or out of the programme.

Transfers into a programme should be treated as follows:

- if patients are smear positive and have been treated for more than one month, commence on Category II regimen; or
- if patients are smear negative, consider the duration and quality of the initial phase treatment, and apply either full continuation phase (if treated more than 2 months), or commence on Category III regimen

Patients who transfer-in, and have documentation of an incomplete course of continuation therapy, but have two negative smear examinations, should complete the continuation phase (as per documentation).

Although these patients are registered, their outcome is usually not evaluated with the 'transfer-in' register. All patients previously treated, who transfer-in and are still sputum smear positive, should be registered as 'Return after interruption' or as 'Failure' and the outcome of their treatment should be evaluated with the cohort of retreatment cases.

7.3 REPATRIATION AND TRANSFERS OUT OF THE PROGRAMME

Repatriation or transfer may occur during the course of treatment if:

- the health services in the area to which the patient is transferring are functioning and are able to cope with additional patients; and
- satisfactory liaison between the 2 programmes is possible to avoid interruption of treatment

\textsuperscript{13} Ideally a programme should aim for cure rates of 85%. However, in the refugee situation the other outcome measures such as patient fatality rate may be high because of concomitant disease, malnutrition, HIV; treatment interruption and transfer-out rates can be high because of instability, either population or political. In these circumstances cure rates of 75-80% are reasonable. Lower rates require careful review to determine why results are inadequate and serious attempts should be made to improve them.
It is very important that continuity of treatment occurs even during transfer. Contact with the new treatment center should be made by the clinic staff if possible prior to transfer. Forward planning and liaison between staff is particularly desirable if a large population is returning home.

All patients should have:

- their personal record card - up to date and with the treatment plan for the rest of the course detailed (a copy of the card should be sent ahead of the patient to the new treatment center if possible)
- adequate drugs to enable them to travel to their new residence and for a short period upon arrival to enable them to establish contact with another clinic; and
- a letter detailing previous treatment, drug doses, adherence etc. which may also be useful if the patient treatment card is lost. A standard template may be made, especially if transfers are common.

In the Central TB register, patients are recorded as transferred out. However, every effort should be made to determine the final outcome and the register updated so that the outcome may be included in the statistics for the relevant cohort.

If the health services in the area to which the patient is transferring into are not functioning or able to cope with extra patients or satisfactory liaison cannot be made to avoid the interruption of treatment, it is preferable for the patients to remain in the camp or present treatment center until treatment can be completed. Many people repatriate to areas where no medical care is available and any further treatment will be impossible. The patients and their families should be counseled regarding the advantages, disadvantages and risks associated with transfer - the risks of delayed repatriation must be balanced with the specific risks of the individual's treatment.

The intensive phase of treatment is crucial in the treatment course. Repatriation or transfer should be delayed until at least this phase has been completed and 2 sputum examinations a month apart are negative (at 2 and 3 months of treatment).

### 7.4 PHASING DOWN OF TB CONTROL PROGRAMMES IN REFUGEE SITUATIONS

The programme must include contingency planning for unstable situations in the area, within the camp, or forced relocation of the refugees. If the situation appears imminent it may be useful to distribute a small supply of drugs to each patient - 3 days for example. These reserve supplies should be prepared when each patient enters the programme but only distributed if needed so as to avoid the sale of the drugs on the black market. No new cases should be recruited during this period. Suspects should be registered, for follow-up at a later date.

The TB control programme should be phased down if:

- population displacement or closure of the camp will be occurring in the next 3 months
- funding is no longer available; or
- security problems are severely interfering with the programme efficiency; e.g. making regular supply of drugs impossible

Admission of new patients to the TB programme should be discontinued a few months before there is likely closure of the camp or movement of displaced persons.
It is usually unreasonable to expect patients to be able to continue treatment if repatriation is intended. The home country is unlikely to have a functioning programme and refugees will have many other priorities when they first return. Patients should not be started on treatment if they are unlikely to be able to complete it.

Every effort should be made to complete treatment for existing patients, even if new patients are not registered. Incomplete treatment is worse than no treatment. Once treatment has commenced, the TB programme has a commitment to the patient to provide a complete course of treatment.

Following closure of a TB programme in an area, the TB register should be sent to the NTP so that enrolled patients may be followed-up to completion of treatment.
Appendix 1
Responsibilities of Key Agencies

In order to implement an effective TB control programme, it should be planned and operationalized at several levels:

National level

- where there is an effective NTP, the NTP will be the lead agency, assisted by WHO, UNHCR and NGOs operating in the country; or
- where the NTP is not functional, the WHO Representative will be the lead officer to assist in the development of a TB control programme in close collaboration with appropriate national agencies, assisted by UNHCR and NGOs operating in the country. In this situation, efforts are to be made to develop an effective NTP

Inter-country level - especially during the repatriation phase and at other periods of mass population movement.

NTP Managers of the host country, the recipient country and any third country (e.g. during transit), assisted by appropriate NGOs - this process will be assisted by various mechanisms:

- WHO Regional participation
- UNHCR participation; and
- inter-country (border) committees

Where the NTP uses WHO / IUATLD endorsed regimens, then the regimen used in the programme should be that used by the NTP. If the NTP is using some other protocol, then advice should be sought from the WHO representative in consultation with the NTP manager. When there is inconsistency between the host country and the country of origin, the decision on drug regime should be referred to an inter-country (border) committee.

Key Agencies

National TB Programme

- responsibility for all TB control activities in the country
- delegation of TB control activities to recognized organizations, as appropriate
- planning, implementing and evaluating the TB control activities in refugee and displaced populations
- coordinating government, international and non-government organizations funding
- drug procurement and distribution
- training
- supervision of TB control activities for refugees and displaced populations; and
- establishment of inter-country (border) committees to coordinate TB control activities in border areas
World Health Organization

- provide technical support, such as development of guidelines and human resource development
- advise on when to commence, and when not to commence, a TB control programme
- assist in the development of a quality control system for drugs
- assist in the arrangements for drug procurement
- assist in advocacy and fund-raising; and
- take the lead role, in the absence of an effective NTP

Office of the United Nations High Commission for Refugees

- secure the camp or emergency setting situation to a point where planning a TB control programme can commence
- support NTP / WHO in planning a TB control programme as a component of general health services
- assist in procurement of TB drugs; and
- support planning, especially in anticipation of, and during, repatriation and mass population movement

Non-government organizations

- operate during the non-secure phases of an emergency – limited relevance to TB control
- monitor health, security and human rights within refugee and displaced populations
- organize health facilities
- implement TB control activities; and
- recognize the supervisory and coordination functions of the NTP / WHO, and provide resources for training, programme management, laboratory, drugs and health promotion
Appendix 2
Job Descriptions and Responsibilities of TB Programme Staff

The number of personnel required and their job descriptions will depend on the local situation. Factors such as the number of refugees or people requiring care in the emergency situation, the site and how spread out the population is will help to determine staffing needs. In large areas, where the affected population is dispersed in a number of different camps or villages, local area coordinators may be required in addition to the overall TB coordinator.

**Lead Agency**
- Ensure adequate funding is available for the programme
- Appoint a suitable TB Coordinator
- Assist with the training of personnel, especially laboratory technicians; and
- Liaise with national authorities, donors and international agencies involved in refugee care

**TB Coordinator**

1. Liaise with National TB Programme
2. Provide leadership, encouragement and advice for problem solving to all staff members
3. Responsible for the production of TB protocol for the camp or emergency settings and their distribution to each treatment post
4. Responsible for the training of camp or local area coordinators
5. Responsible for setting up the programme in all the camps (and any sites for Internally Displaced Persons)
6. Coordinate training of programme staff including 2 laboratory technicians for each laboratory
7. Supervise overall functioning of the programme
8. Ensure quality control of all aspects of the programme including the laboratory
9. Ensure adequate stocks are available at all times
10. Ensure continuing education programmes for staff and the community
11. Visit the laboratory regularly and record all new patients in the central register
12. Maintain the Central TB register up-to-date
13. Ensure follow-up all patients, especially transfers and difficult patients; and
14. Coordinate management of all TB-related information.

**Health Workers**
- Liaise with laboratory to ensure all sputum positive patients are followed up
- Ensure all records are kept up-to-date and are accurate
- Ensure all follow-up sputum tests are performed as required and results recorded
- Provide feedback of clinic results to CHWs and other staff

14 This is the only position dedicated to TB control.
• Ensure all patients are treated with respect and compassion by clinic staff
• Ensure clinic hours are suitable for the patients and long waits are not encountered
• Ensure incentives are distributed appropriately
• Implement continuing education programmes in the clinic
• Ensure all who fail to attend for treatment are followed up
• Check supplies are adequate (including emergency stock) and orders placed in a timely manner
• Liaise with camp or emergency setting coordinator; and
• Provide continuing education programmes for staff and the community

**Community Health Workers**
• Refer anyone with symptoms suspicious of TB to the clinic
• Educate community, patients and relatives re TB and its management
• Supervise directly observed therapy administration to patients for whom they are responsible
• Record all treatments given in clinic records and on patient's record card
• Identify defaulters, 'returnees' and 'missing'; and
• Follow-up non-compliers and defaulters

**Laboratory Technician**
• Examine all smears sent for AFB examination and accurately report the findings. Reports should include whether the sample was saliva or sputum, whether AFBs were seen and if so in what numbers (e.g. scale from ++++ to +)
• Supply regular written reports to the clinic supervisor of all smear results, both positive and negative, and
• Keep a list of all new smear positive patients, the date of diagnosis, when and who notified
Appendix 3
Adverse Effects of Anti-TB Drugs

Adverse effects are classified as minor or major. In general, a patient who develops minor adverse effects should continue the anti-TB treatment, usually at the same dose but sometimes at a reduced dose. The patient also receives symptomatic treatment. If a patient develops a major side effect, the treatment or the offending drug is stopped. Patients with major adverse reactions should be managed in a hospital.

<table>
<thead>
<tr>
<th>Side Effects</th>
<th>Drug(s) probably responsible</th>
<th>Management</th>
</tr>
</thead>
<tbody>
<tr>
<td>MINOR</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anorexia, nausea, abdominal pain</td>
<td>Rifampicin</td>
<td>Give drugs last thing at night</td>
</tr>
<tr>
<td>Joint pains</td>
<td>Pyrazinamide</td>
<td>Aspirin</td>
</tr>
<tr>
<td>Burning sensation in the feet</td>
<td>Isoniazid</td>
<td>Pyridoxine 100mg daily</td>
</tr>
<tr>
<td>Orange/red urine</td>
<td>Rifampicin</td>
<td>Reassurance</td>
</tr>
<tr>
<td>MAJOR</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Itching of skin, rash</td>
<td>Streptomycin</td>
<td>Stop anti-TB drugs</td>
</tr>
<tr>
<td>Deafness</td>
<td>Streptomycin</td>
<td>Stop streptomycin use ethambutol</td>
</tr>
<tr>
<td>Dizziness</td>
<td>Streptomycin</td>
<td>Stop streptomycin use ethambutol</td>
</tr>
<tr>
<td>Jaundice</td>
<td>Most anti-TB drugs (especially isoniazid, pyrazinamide and rifampicin)</td>
<td>Stop anti-TB drugs</td>
</tr>
<tr>
<td>Vomiting and confusion</td>
<td>Most anti-TB drugs</td>
<td>Stop anti-TB drugs</td>
</tr>
<tr>
<td>Visual impairment</td>
<td>Ethambutol</td>
<td>Stop ethambutol</td>
</tr>
<tr>
<td>Shock, purpura, acute renal failure</td>
<td>Rifampicin</td>
<td>Stop rifampicin</td>
</tr>
</tbody>
</table>

Management of a cutaneous reaction - the recommended approach is to try symptomatic treatment with anti-histamines, continue anti-TB treatment, and observe the patient closely. However, if a skin rash develops then all anti-TB drugs must be stopped.
Appendix 4
Estimating Drug Requirements

Drug Requirements
To estimate the requirements of an initial order of drugs for the first year, follow these steps:

- Define the treatment regimens to be adopted, then define the drugs to be used for each category of patient, the number of weight groups to be differentiated, and the dosages for each.
- Calculate the drug requirement per patient for each category (see table).
- Estimate the number of smear-positive cases based on epidemiological data (e.g. Africa and Asia 100 per 100,000; Latin America and the former USSR 50 per 100,000).
- Estimate the number of adult patients in each category to be treated. When a large population is displaced, the proportion of patients whose treatment has been interrupted is high during the first year. For example, with Rwandan refugees (October, 1994), the estimate for each 100,000 population was:
  - 50 Category I patients (new smear positive cases with 10% severe smear-negative)
  - 20 Category II patients (failures, relapses, and smear-positive cases after interruption of treatment); and
  - 30 Category III patients
- Calculate total estimated drug requirements for adults.
- Add 10% to the quantity of each drug (or combination drug) to provide for children and some wastage; and then
- Add 50% for reserve stock to the first purchase.

For planning purposes, add an additional 50% to costs, to cover transportation and distribution.

Review drug usage after the first three months and, based on consumption during that period, recalculate requirements for the rest of the year. Place orders well in advance to ensure continuity in supply. Note that requirements may increase if treatment is seen to be successful, as more suspected cases will be encouraged to come forward.

The drug cost (FOB) of a full course of treatment in 1997 is approximately $26 per new patient (Category I); $61 for retreatment (Category II); $20 per new patient (Category III).

Distributing and administering four separate drugs simultaneously – and ensuring that all are available and taken together every time – poses considerable logistic and supervisory problems.

Combination tablets (i.e. isoniazid + rifampicin, or isoniazid + ethambutol) can simplify matters (and could even make self-administration a possibility in certain cases).

Some countries with large TB programmes, special "blister packs" are produced in which three or four tablets, corresponding to the daily requirement for the particular treatment regime adopted, are packaged together. These packs should be used wherever they are already being produced, and made available for a national programme.
**EXAMPLES OF TREATMENT REGIMENS AND DRUG REQUIREMENTS**

<table>
<thead>
<tr>
<th></th>
<th>HR 100mg+150mg</th>
<th>Z 400mg or 500mg</th>
<th>E 400mg</th>
<th>S 1gm</th>
<th>H 300mg</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Cat I</strong></td>
<td>1st 2 months then next 4 months</td>
<td>4 daily 4,3x per week</td>
<td>4 daily -</td>
<td>3 daily -</td>
<td>- - 1,3x per week</td>
</tr>
<tr>
<td><strong>Cat II</strong></td>
<td>1st 3 months then next 5 months</td>
<td>4 daily 4,3x per week</td>
<td>4 daily -</td>
<td>3 daily 4,3x per week</td>
<td>1 daily (for 3 months) 1,3x per week</td>
</tr>
<tr>
<td><strong>Cat III</strong></td>
<td>1st 2 months then next 4 months</td>
<td>4 daily 4,3x per week</td>
<td>4 daily -</td>
<td>- - -</td>
<td>- - 1,3x per week</td>
</tr>
</tbody>
</table>

*Plus water for injection (5ml), a disposable syringe and a needle.

**TOTAL REQUIREMENTS/PATIENT (INITIAL AND CONTINUATION PHASES)**

<table>
<thead>
<tr>
<th></th>
<th>HR 100mg+150mg</th>
<th>Z 400mg or 500mg</th>
<th>E 400mg</th>
<th>S 1gm*</th>
<th>H 300mg</th>
<th>EH 400mg+150mg</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Cat I</strong></td>
<td>470</td>
<td>250</td>
<td>180</td>
<td>-</td>
<td>50</td>
<td>360</td>
</tr>
<tr>
<td><strong>Cat II</strong></td>
<td>620</td>
<td>360</td>
<td>530</td>
<td>60</td>
<td>70</td>
<td>-</td>
</tr>
<tr>
<td><strong>Cat III</strong></td>
<td>470</td>
<td>250</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>360</td>
</tr>
</tbody>
</table>

* Plus water for injection (5ml), a disposable syringe and a needle.

**15 These dosages are appropriate for persons >50kg in weight.**
## PROGRAMMES USING FIXED-DOSE COMBINATIONS

<table>
<thead>
<tr>
<th>Cat</th>
<th>1st 2 mths then next 4 mths or next 6 mths</th>
<th>HR 100mg+150mg</th>
<th>EH 400mg+150mg</th>
<th>E 400mg</th>
<th>S 1gm</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cat I</td>
<td></td>
<td>-</td>
<td>-</td>
<td>3 daily</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2 daily</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Cat II</td>
<td></td>
<td>-</td>
<td>-</td>
<td>3 daily</td>
<td>1gm per day (for 2 mths only)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2 daily</td>
<td>-</td>
<td>4, 3x per wk</td>
<td></td>
</tr>
<tr>
<td>Cat III</td>
<td></td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

## PROGRAMMES USING FIXED-DOSE COMBINATIONS – TOTAL REQUIREMENTS/PATIENT (INITIAL AND CONTINUATION PHASE)

<table>
<thead>
<tr>
<th>Cat</th>
<th>6 mth regimen</th>
<th>8 mth regimen</th>
<th>HR 100mg+150mg</th>
<th>EH 400mg+150mg</th>
<th>E 400mg</th>
<th>S 1gm</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cat I</td>
<td>160</td>
<td>-</td>
<td>180</td>
<td>180</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Cat II</td>
<td>180</td>
<td>-</td>
<td>240</td>
<td>180</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Cat III</td>
<td>160</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>-</td>
<td>360</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>
# Appendix 5
## Price list of Anti-TB Drugs

<table>
<thead>
<tr>
<th>Drug</th>
<th>Dosage Form</th>
<th>Dosage Strength</th>
<th>Quantity</th>
<th>UNICEF price(^\text{16}) (USD)</th>
<th>Lowest price obtainable(^\text{17}) (USD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>H</td>
<td>Tablet</td>
<td>100mg</td>
<td>1000</td>
<td>2.90</td>
<td>2.30</td>
</tr>
<tr>
<td></td>
<td></td>
<td>300mg</td>
<td>1000</td>
<td>8.32</td>
<td>5.80</td>
</tr>
<tr>
<td>R</td>
<td>Capsule or</td>
<td>150mg</td>
<td>1000</td>
<td>38.7</td>
<td>25.7</td>
</tr>
<tr>
<td></td>
<td>tablet</td>
<td>300mg</td>
<td>1000</td>
<td>55.4</td>
<td>46.5</td>
</tr>
<tr>
<td>Z</td>
<td>Tablet</td>
<td>500mg</td>
<td>1000</td>
<td>34.20</td>
<td>31.5</td>
</tr>
<tr>
<td>E</td>
<td>Tablet</td>
<td>400mg</td>
<td>1000</td>
<td>25.10</td>
<td>18.3</td>
</tr>
<tr>
<td>S</td>
<td>Powder for</td>
<td>1g base in</td>
<td>100</td>
<td>23.84</td>
<td>7.3</td>
</tr>
<tr>
<td></td>
<td>injection</td>
<td>vial</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Vial</td>
<td>5ml</td>
<td>100</td>
<td>1.56</td>
<td>2.67</td>
</tr>
<tr>
<td></td>
<td>Disposable</td>
<td></td>
<td>100</td>
<td>-</td>
<td>2.8</td>
</tr>
<tr>
<td></td>
<td>syringe +</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>needle</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EH</td>
<td>Tablet</td>
<td>400mg</td>
<td>1000</td>
<td>-</td>
<td>22</td>
</tr>
<tr>
<td></td>
<td></td>
<td>+ 150mg</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RH</td>
<td>Tablet</td>
<td>150mg</td>
<td>1000</td>
<td>-</td>
<td>24</td>
</tr>
<tr>
<td></td>
<td></td>
<td>+ 100mg</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>+ 300mg</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>+ 150mg</td>
<td></td>
<td></td>
<td>55</td>
</tr>
</tbody>
</table>

\(^{16}\) The free on board (FOB) price of purchases ordered through UNICEF is calculated by adding 6% to the price indicated in: UNICEF, Essential drugs price list, Jan-June 1997 (Address – Supply Division, UNICEF PLADS, Free port, DK 2100 Copenhagen, DENMARK, Fax: (+45) 3526 94 21.

\(^{17}\) Usually FOB price (including handling charges, excluding insurance and freight): special tariff 1996 (except as otherwise indicated) applied to international aid organizations for national programmes. See other prices in: International drug price indicator guide, Management Sciences for Health, 1995 (address: MSH, Drug Management Programme, 1655 North Fort Drive, Suite 920, Arlington, VA 22209-3108, USA. Fax: (703) 524 7898).
Appendix 6
Some Suppliers of Anti-TB Drugs

Action Medeo
Deutches Medikamenten-Hilfswerk
St Töniser Strasse 21
D-4154 Toenisvörst 2, Germany
Fax: (49-21-56) 80632

ECHO (ECHO International Health Services Limited)
Ullswater Crescent
Coulsdon, Surrey CR5 2HR, United Kingdom
Fax: (44-181) 6680751

IAPS (International Association for Procurement and Supply)
Rode Kruisstraat 20
PO Box 37030
1030 AA Amsterdam, The Netherlands
Fax: (31-20) 6343401

IDA (International Dispensary Association)
PO Box 37098
1030 AB Amsterdam, The Netherlands
Fax: (31-20) 4031854

KCR International
45, rue de la Libération
78350 Jouy-en-Josas, France
Fax: (33-1) 39565355

Orbi-Pharma
Van Trierstraat 40
B 2018 Antwerp, Belgium
Fax: (32-3) 2169897

For a recent copy of the UNICEF Essential Drugs Price List, write to:

UNICEF
Unicef Plads
Freeport
DK-2100
Copenhagen
Denmark
Fax: (45) 269421

For the International Drug Price Indicator Guide, write to:

Management Sciences for Health
Drug Management Programme
1655 North Fort Myer Drive
Suite 920
Arlington, VA 22209
USA
### Appendix 7

**Laboratory Requirements for Smear Examination**

Microscopy examination for 2000 specimens

Binocular microscopy for use in daylight and electric power, with oil immersion objective (×100), eye-pieces (×8 or ×10) and spare bulbs for microscope. In hot and humid climate, warm cupboard heated by 1 or 2 light bulbs (40 Watts) is also needed.

<table>
<thead>
<tr>
<th>Equipment</th>
<th>Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Plastic, disposable sputum containers, 45 to 50ml</td>
<td>3000</td>
</tr>
<tr>
<td>Slides for microscope, 25x75, 1.1-1.3mm thick</td>
<td>3000</td>
</tr>
<tr>
<td>Applicators, wooden or nickel-chrome wire, 1mm diameter</td>
<td>3000</td>
</tr>
<tr>
<td>Loop holder</td>
<td>50cm</td>
</tr>
<tr>
<td>Slide holder made of metal (12 to 25 slides), 40cm x 5cm</td>
<td>2</td>
</tr>
<tr>
<td>Bunsen burner for use with butane gas with butane gas cylinders</td>
<td>2</td>
</tr>
<tr>
<td>or spirit lamp cotton wool plug or metal wire</td>
<td>2</td>
</tr>
<tr>
<td>Glass marker, diamond point</td>
<td>2</td>
</tr>
<tr>
<td>Timer, 0-60 min with alarm</td>
<td>1</td>
</tr>
<tr>
<td>Forceps, stainless steel for slides, 15cm</td>
<td>2</td>
</tr>
<tr>
<td>Scissors, stainless, 25cm</td>
<td>1</td>
</tr>
<tr>
<td>Slides rack made of plastic for 12-25 slides</td>
<td>2</td>
</tr>
<tr>
<td>Slides boxes for 100 slides</td>
<td>2</td>
</tr>
<tr>
<td>Funnel glass 45mm or 60mm diameter</td>
<td>4</td>
</tr>
<tr>
<td>Funnel glass 90mm or 125mm diameter</td>
<td>4</td>
</tr>
<tr>
<td>Drop bottles, glass, 100ml</td>
<td>4</td>
</tr>
<tr>
<td>Bottles, brown glass, 100ml</td>
<td>4</td>
</tr>
<tr>
<td>Flasks, glass or pyres, 500ml</td>
<td>3</td>
</tr>
<tr>
<td>Flasks, brown glass, 1000ml</td>
<td>2</td>
</tr>
<tr>
<td>Bowl made of plastic, 50cmx30cm</td>
<td>2</td>
</tr>
<tr>
<td>Wash bottles made of plastic 500ml</td>
<td>2</td>
</tr>
<tr>
<td>Drop plastic bottles 10ml for immersion oil</td>
<td>2</td>
</tr>
<tr>
<td>Bucket made of plastic 12ml</td>
<td>2</td>
</tr>
<tr>
<td>Acid-ethanol for ziehl-neelsen staining</td>
<td>3 litres</td>
</tr>
<tr>
<td>Carbon fuchsin for ziehl-neelsen staining</td>
<td>6 litres</td>
</tr>
<tr>
<td>Aqueous methylene bleu</td>
<td>4 litres</td>
</tr>
<tr>
<td>Immersion oil</td>
<td>200ml</td>
</tr>
<tr>
<td>Xylene or toluene</td>
<td>200ml</td>
</tr>
<tr>
<td>Lab request forms</td>
<td>3000</td>
</tr>
<tr>
<td>Lab register for TB</td>
<td>1</td>
</tr>
<tr>
<td>Pens,</td>
<td>2</td>
</tr>
<tr>
<td>Adhesive labels for sputum containers</td>
<td>3000</td>
</tr>
<tr>
<td>Lens paper</td>
<td>2 rolls</td>
</tr>
<tr>
<td>Ball of white absorbent cotton</td>
<td>500g</td>
</tr>
<tr>
<td>Filter paper 15cm diameter, no 1</td>
<td>4 boxes</td>
</tr>
<tr>
<td>Toilet tissues</td>
<td>2 rolls</td>
</tr>
<tr>
<td>Pressure cooker</td>
<td>1</td>
</tr>
<tr>
<td>Still</td>
<td>1</td>
</tr>
<tr>
<td>Towel and clean rags</td>
<td>As needed</td>
</tr>
<tr>
<td>Masks and overall</td>
<td>As needed</td>
</tr>
<tr>
<td>Sodium hypochlorite</td>
<td>10 litres</td>
</tr>
<tr>
<td>Methylated spirits</td>
<td>2 litres</td>
</tr>
</tbody>
</table>
Appendix 8
Estimate the Quantity of Forms, Registers and Health Education Materials

Estimate the quantity of TB forms, registers, and education materials needed during the first year. They will need to be ordered and distributed on a yearly basis.18

Determine the minimum quantity of forms, registers, and health education materials needed for the year.

Refer to the table below that lists the recommended quantity of forms and registers. Your country may need additional forms.

<table>
<thead>
<tr>
<th>Name of forms and registers</th>
<th>Qty needed for each NDT District</th>
</tr>
</thead>
<tbody>
<tr>
<td>TB treatment card</td>
<td>1 per patient</td>
</tr>
<tr>
<td>TB ID card</td>
<td>1 per patient</td>
</tr>
<tr>
<td>District TB register</td>
<td>1 per year</td>
</tr>
<tr>
<td>TB lab register</td>
<td>1 per year</td>
</tr>
<tr>
<td>TB lab form request for sputum exam</td>
<td>13 for every new pulmonary smear-positive case</td>
</tr>
<tr>
<td>TB culture, sensitivity test request, report form</td>
<td>Country specific</td>
</tr>
<tr>
<td>Quarterly report on new cases and relapses of TB</td>
<td>12 per year (3 copies x 4 quarters)</td>
</tr>
<tr>
<td>Quarterly report on the results of treatment of pulmonary TB patients registered 12-15 months earlier</td>
<td>12 per year (3 copies x 4 quarters)</td>
</tr>
<tr>
<td>TB referral, transfer form</td>
<td>Based on proportion of patients who transferred out of the district during the previous year</td>
</tr>
</tbody>
</table>

Add an additional 20% to the quantity of forms, registers, and education materials needed.

To account for the increase of tuberculosis patients and lost forms, add 20% to the quantity of forms, registers, and educational materials needed. (You do not have to make this calculation for the registers because one of each register book should be sufficient for 1 year).

18 Examples of recommended forms can be found in International Union Against Tuberculosis and Lung Disease (IUATLD) Tuberculosis Guide for Low Income Countries. 4th ed. 1996. Also World Health Organization, Managing Tuberculosis at District Level. 1994.
BIBLIOGRAPHY AND RESOURCES

Bigot A, Varaine F. Programmes de lutte contre la tuberculose. 2nd Ed. MSF 1996.


International Union Against Tuberculosis and Lung Disease (IUATLD) Tuberculosis Guide for Low Income Countries. 4th ed. 1996

Kessler C. Tuberculosis Control in Refugees A Focus on Developing Countries. Dissertation, London School of Hygiene and Tropical Medicine, 1995.


Perrin P. International Committee of the Red Cross War and Public Health 1996.


Global Tuberculosis Programme

WORLD HEALTH ORGANIZATION

20, Avenue Appia
CH - 1211 GENEVA 27
SWITZERLAND

Telephone 41 22 791 2963
Facsimile 41 22 791 4199

Change to English version
Change to French version
Change to Spanish version

View this page in text format